

Press Release July 3, 2017

## Invitation to Infant Bacterial Therapeutics Capital Markets Day 2017

Infant Bacterial Therapeutics has the pleasure to invite investors, financial analysts and media to attend our Capital Markets Day in Stockholm on September 8, 2017

The event is taking place at Svenska Läkaresällskapet, Klara Östra Kyrkogata 10, Stockholm starting at 9.30 and ending at approximately 12.00

The purpose of the Capital Markets Day is to present Infant Bacterial Therapeutics business, information about the disease necrotizing enterocolitis, the IBP-9414 project, gastroschisis and the IBP-1016 project.

### Agenda

#### *Introduction*

Peter Rothschild, Chairman of the Board, IBT  
Staffan Strömberg PhD, Chief Executive Officer, IBT

#### *What is Necrotizing Enterocolitis*

Professor Josef Neu MD, Department of Pediatrics, Division of Neonatology, Univ.  
Florida, Gainesville

#### *Why IBP-9414 for Necrotizing Enterocolitis*

#### *Gastroschisis and IBP-1016 – A New Opportunity*

Eamonn Connolly PhD, Chief Scientific Officer, IBT

#### *Pharmaceutical Development of IBP-9414 – Breaking New Ground*

Agneta Heierson PhD, Vice President, Clinical Development, IBT  
Anders Kronström M.Sc., M.B.A., Chief Technical Officer, IBT

#### *A Globally Valuable Pharmaceutical*

Daniel Mackey, Chief Financial Officer, IBT

#### *Closing Remarks*

Staffan Strömberg PhD, Chief Executive Officer, IBT

Attendance: If you would like to participate in the event, please register by sending a mail to [ibt@ibtherapeutics.com](mailto:ibt@ibtherapeutics.com)

Further information will also be available on Infant Bacterial Therapeutics website in advance of the event.

### **About Infant Bacterial Therapeutics AB**

Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of *Lactobacillus reuteri*, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis ("NEC"), a fatal, rare disease that afflicts premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.



**INFANT BACTERIAL THERAPEUTICS**

**Press Release July 3, 2017**

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.  
[www.ibtherapeutics.com](http://www.ibtherapeutics.com)

**For additional information please contact**

Staffan Strömberg, CEO  
Infant Bacterial Therapeutics AB  
Bryggargatan 10  
111 21 Stockholm  
Phone: +46 8 410 145 55  
[info@ibtherapeutics.com](mailto:info@ibtherapeutics.com)  
[www.ibtherapeutics.com](http://www.ibtherapeutics.com)



**INFANT BACTERIAL THERAPEUTICS**